UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The MSBase registry: Informing clinical practice

Multiple Sclerosis Journal, 2019-12, Vol.25 (14), p.1828-1834

2019

Volltextzugriff (PDF)

Treatment decisions in multiple sclerosis - insights from real-world observational studies

Nature reviews. Neurology, 2017-02, Vol.13 (2), p.105-118

2017

Volltextzugriff (PDF)

Vitamin D for the treatment of multiple sclerosis: a meta-analysis

Journal of neurology, 2018-12, Vol.265 (12), p.2893-2905

2018

Volltextzugriff (PDF)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

Multiple sclerosis, 2018-06, Vol.24 (7), p.963-973

2018

Volltextzugriff (PDF)

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Lancet neurology, 2017-03, Vol.16 (3), p.189-199

2017

Volltextzugriff (PDF)

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

Multiple sclerosis, 2021-09, Vol.27 (10), p.1543-1555

2021

Volltextzugriff (PDF)

Brain health: time matters in multiple sclerosis

Multiple sclerosis and related disorders, 2016-09, Vol.9, p.S5-S48

2016

Volltextzugriff (PDF)

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis

Multiple sclerosis, 2023-08, Vol.29 (9), p.1126-1135

2023

Volltextzugriff (PDF)

Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?

Frontiers in immunology, 2019-09, Vol.10, p.2066-2066

2019

Volltextzugriff (PDF)

Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis

Multiple sclerosis, 2023-04, Vol.29 (4-5), p.540-548

2023

Volltextzugriff (PDF)

The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis

Neurotherapeutics, 2020-10, Vol.17 (4), p.1768-1784

2020

Volltextzugriff (PDF)

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Journal of neurology, neurosurgery and psychiatry, 2016-10, Vol.87 (10), p.1133-1137

2016

Volltextzugriff (PDF)

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Multiple sclerosis, 2021-04, Vol.27 (5), p.719-728

2021

Volltextzugriff (PDF)

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy

Multiple sclerosis, 2021-03, Vol.27 (3), p.465-474

2021

Volltextzugriff (PDF)

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients

Scientific reports, 2020-12, Vol.10 (1), p.22217-10, Article 22217

2020

Volltextzugriff (PDF)

Fingolimod after natalizumab and the risk of short-term relapse

Neurology, 2014-04, Vol.82 (14), p.1204-1211

2014

Volltextzugriff (PDF)

International consensus on quality standards for brain health-focused care in multiple sclerosis

Multiple sclerosis, 2019-11, Vol.25 (13), p.1809-1818

2019

Volltextzugriff (PDF)

Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis

Scientific reports, 2024-01, Vol.14 (1), p.1436-1436, Article 1436

2024

Volltextzugriff (PDF)

Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study

Scientific reports, 2024-01, Vol.14 (1), p.122-122, Article 122

2024

Volltextzugriff (PDF)

The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis

Therapeutic advances in neurological disorders, 2019-07, Vol.12, p.1756286419859183-1756286419859183

2019

Volltextzugriff (PDF)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Therapeutic advances in neurological disorders, 2021, Vol.14, p.17562864211042458-17562864211042458

2021

Volltextzugriff (PDF)

Prediction of relapse activity when switching to cladribine for multiple sclerosis

Multiple sclerosis, 2023-01, Vol.29 (1), p.119-129

2023

Volltextzugriff (PDF)

Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis

Cerebellum (London, England), 2020-10, Vol.19 (5), p.691-700

2020

Volltextzugriff (PDF)

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease

BMC neurology, 2022-03, Vol.22 (1), p.84-10, Article 84

2022

Volltextzugriff (PDF)

1 – 25 von 473

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(444)
Mit Volltextzugriff
(340)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(305)
Life Sciences & Biomedicine
(281)
Multiple Sclerosis
(227)
Neurosciences & Neurology
(210)
Clinical Neurology
(186)
Humans
(182)
Neurosciences
(124)
Female
(103)
Male
(95)
Adult
(86)
Neurology
(76)
Middle Aged
(61)
Patients
(59)
Disease Progression
(40)
Magnetic Resonance Imaging
(39)
Multiple Sclerosis - Drug Therapy
(38)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(36)
Medicine
(33)
Multiple Sclerosis - Genetics
(31)
Recurrence
(29)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(83)
Journal Of Neurology, Neurosurgery And Psychiatry
(36)
Bmj Neurology Open
(35)
Multiple Sclerosis
(35)
Multiple Sclerosis And Related Disorders
(24)
Plos One
(23)
Journal Of Clinical Neuroscience
(22)
Abstracts
(10)
Autoimmunity Reviews
(10)
Brain
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

The MSBase registry: Informing clinical practice

Treatment decisions in multiple sclerosis - insights from real-world observational studies

Vitamin D for the treatment of multiple sclerosis: a meta-analysis

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network

Brain health: time matters in multiple sclerosis

Association between clinic-level quality of care and patient-level outcomes in multiple sclerosis

Innate Immunity in the Central Nervous System: A Missing Piece of the Autoimmune Encephalitis Puzzle?

Choroid plexus volume is enlarged in clinically isolated syndrome patients with optic neuritis

The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Real-world disability improvement in patients with relapsing–remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy

Epigenetic differences at the HTR2A locus in progressive multiple sclerosis patients

Fingolimod after natalizumab and the risk of short-term relapse

International consensus on quality standards for brain health-focused care in multiple sclerosis

Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis

Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study

The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)

Prediction of relapse activity when switching to cladribine for multiple sclerosis

Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

Failure of alemtuzumab therapy in three patients with MOG antibody associated disease

Suchergebnisse filtern